158 related articles for article (PubMed ID: 20840324)
1. Transforming growth factor β-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation.
Descazeaud A; Weinbreck N; Robert G; Vacherot F; Abbou CC; Labrousse F; Allory Y; Rubin MA; de la Taille A
BJU Int; 2011 Jul; 108(2 Pt 2):E23-8. PubMed ID: 20840324
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.
Theyer G; Kramer G; Assmann I; Sherwood E; Preinfalk W; Marberger M; Zechner O; Steiner GE
Lab Invest; 1992 Jan; 66(1):96-107. PubMed ID: 1370561
[TBL] [Abstract][Full Text] [Related]
3. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis.
Robert G; Descazeaud A; Nicolaïew N; Terry S; Sirab N; Vacherot F; Maillé P; Allory Y; de la Taille A
Prostate; 2009 Dec; 69(16):1774-80. PubMed ID: 19670242
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates.
De Miguel P; Royuela ; Bethencourt R; Ruiz A; Fraile B; Paniagua R
Cytokine; 1999 Sep; 11(9):722-7. PubMed ID: 10479409
[TBL] [Abstract][Full Text] [Related]
5. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma.
Ebelt K; Babaryka G; Figel AM; Pohla H; Buchner A; Stief CG; Eisenmenger W; Kirchner T; Schendel DJ; Noessner E
Prostate; 2008 Jan; 68(1):1-10. PubMed ID: 17948280
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-beta expression in prostate neoplasia.
Cardillo MR; Petrangeli E; Perracchio L; Salvatori L; Ravenna L; Di Silverio F
Anal Quant Cytol Histol; 2000 Feb; 22(1):1-10. PubMed ID: 10696454
[TBL] [Abstract][Full Text] [Related]
7. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y
J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
Hussein MR; Al-Assiri M; Musalam AO
Exp Mol Pathol; 2009 Apr; 86(2):108-13. PubMed ID: 19111537
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor beta 1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma.
Royuela M; De Miguel MP; Bethencourt FR; Sanchez-Chapado M; Fraile B; Paniagua R
Growth Factors; 1998; 16(2):101-10. PubMed ID: 9932228
[TBL] [Abstract][Full Text] [Related]
10. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
11. Prostate Biopsy Markers of Inflammation are Associated with Risk of Clinical Progression of Benign Prostatic Hyperplasia: Findings from the MTOPS Study.
Torkko KC; Wilson RS; Smith EE; Kusek JW; van Bokhoven A; Lucia MS
J Urol; 2015 Aug; 194(2):454-61. PubMed ID: 25828974
[TBL] [Abstract][Full Text] [Related]
12. [Relation between the prostatic tissue components and natural history, estrogen receptor].
Matsuda T; Abe H; Suda K
Rinsho Byori; 2003 Dec; 51(12):1180-3. PubMed ID: 14743740
[TBL] [Abstract][Full Text] [Related]
13. Different perforin expression in peripheral blood and prostate tissue in patients with benign prostatic hyperplasia and prostate cancer.
Tokmadžić VS; Tomaš MI; Sotošek S; Laškarin G; Dominović M; Tulić V; Dorđević G; Sustić A; Mrakovčić-Šutić I
Scand J Immunol; 2011 Oct; 74(4):368-76. PubMed ID: 21535078
[TBL] [Abstract][Full Text] [Related]
14. CD4+ and CD8+ T-lymphocyte scores cannot reliably predict progression in patients with benign prostatic hyperplasia.
Lamb AD; Qadan M; Roberts S; Timlin H; Vowler SL; Campbell FM; Grigor K; Bartlett JM; McNeill SA
BJU Int; 2011 Jul; 108(2 Pt 2):E43-50. PubMed ID: 21457430
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.
Royuela M; Ricote M; Parsons MS; García-Tuñón I; Paniagua R; de Miguel MP
J Pathol; 2004 Jan; 202(1):41-9. PubMed ID: 14694520
[TBL] [Abstract][Full Text] [Related]
16. Stromal cells of the human prostate: initial isolation and characterization.
Kassen A; Sutkowski DM; Ahn H; Sensibar JA; Kozlowski JM; Lee C
Prostate; 1996 Feb; 28(2):89-97. PubMed ID: 8604397
[TBL] [Abstract][Full Text] [Related]
17. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy.
Shariat SF; Menesses-Diaz A; Kim IY; Muramoto M; Wheeler TM; Slawin KM
Urology; 2004 Jun; 63(6):1191-7. PubMed ID: 15183988
[TBL] [Abstract][Full Text] [Related]
18. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells.
Vignozzi L; Cellai I; Santi R; Lombardelli L; Morelli A; Comeglio P; Filippi S; Logiodice F; Carini M; Nesi G; Gacci M; Piccinni MP; Adorini L; Maggi M
J Endocrinol; 2012 Jul; 214(1):31-43. PubMed ID: 22562653
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
[TBL] [Abstract][Full Text] [Related]
20. Regulation of proliferation and differentiation of prostatic stromal cells by oestradiol through prostatic epithelial cells in a paracrine manner.
Wu Q; Shi J; Chen L; Wang CY; Park I; Lee C; Zhang J
BJU Int; 2008 Feb; 101(4):497-502. PubMed ID: 18190643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
